Jounce Therapeutics Secures $56,000,000 Series B Funding

  • Feed Type
  • Date
    4/23/2015
  • Company Name
    Jounce Therapeutics
  • Mailing Address
    1030 Massachusetts Avenue Cambridge, MA 02138 USA
  • Company Description
    Jounce Therapeutics is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient’s tumor directly, but instead by harnessing the patient’s immune system to seek out and attack cancerous cells and tumors.
  • Website
    http://www.jouncetx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $56,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Jounce’s pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. In addition, the investment will support expanded discovery of novel treatments aimed at tumors that may be less likely to respond to T cell checkpoint monotherapy, including therapies that target innate immune and stromal cells.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy